Search

Your search keyword '"McCluggage, W Glenn"' showing total 1,157 results
Start Over Author "McCluggage, W Glenn" Publication Type Academic Journals

Refine your results

more »

more »

more »

more »

more »
1,157 results on '"McCluggage, W Glenn"'

5. Unraveling the Molecular Landscape of Uterine Tumor Resembling Ovarian Sex Cord Tumor: Insights From A Clinicopathological, Morphologic, Immunohistochemical, and Molecular Analysis of 35 Cases

Author

Flídrová, Miroslava, Hájková, Nikola, Hojný, Jan, Dvořák, Jiří, Michálková, Romana, Krkavcová, Eva, Laco, Jan, McCluggage, W. Glenn, Giordano, Giovanna, Silini, Enrico Maria, Michalová, Květoslava, Bizoń, Magdalena, Němejcová, Kristýna, Dundr, Pavel, and Kendall Bártů, Michaela

Published
2024
Full Text
View/download PDF

7. A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors

Author

Němejcová, Kristýna, Bártů, Michaela Kendall, Michálková, Romana, Drozenová, Jana, Fabian, Pavel, Fadare, Oluwole, Hausnerová, Jitka, Laco, Jan, Matěj, Radoslav, Méhes, Gábor, Singh, Naveena, Stolnicu, Simona, Škapa, Petr, Švajdler, Marián, Stružinská, Ivana, Cibula, David, Kocian, Roman, Lax, Sigurd F., McCluggage, W. Glenn, and Dundr, Pavel

Published
2023
Full Text
View/download PDF

9. Classifying Anal Intraepithelial Neoplasia 2 Based on LAST Recommendations.

Author

Liu, Yuxin, McCluggage, W Glenn, Darragh, Teresa M, Zheng, Wenxin, Roberts, Jennifer M, Park, Kay J, Hui, Pei, Blakely, Morgan, Sigel, Keith, and Gaisa, Michael M

Subjects
Cancer, Anus Neoplasms, Biomarkers, Tumor, Biopsy, Cyclin-Dependent Kinase Inhibitor p16, Female, Humans, Papillomaviridae, Papillomavirus Infections, Squamous Intraepithelial Lesions, Uterine Cervical Neoplasms, Interobserver agreement, Human papillomavirus, Anal intraepithelial neoplasia 2, p16 Immunohistochemistry, Medical and Health Sciences, Pathology
Abstract

ObjectivesThe Lower Anogenital Squamous Terminology (LAST) recommendations classify human papillomavirus-associated squamous lesions into low- and high-grade squamous intraepithelial lesions (LSILs/HSILs). Our study aimed to assess interobserver agreement among 6 experienced pathologists in assigning 40 anal lesions previously diagnosed as anal intraepithelial neoplasia 2 (AIN 2) to either HSIL or non-HSIL categories.MethodsAgreement based on photomicrographs of H&E alone or H&E plus p16 immunohistochemistry was calculated using κ coefficients.ResultsAgreement was fair based on H&E alone (κ = 0.42; 95% confidence interval [CI], 0.34-0.52). Adding p16 improved agreement to moderate (κ = 0.55; 95% CI, 0.54-0.62). On final diagnosis, 21 cases (53%) had unanimous diagnoses, and 19 (47%) were divided. When designating p16 results as positive or negative, agreement was excellent (κ = 0.92; 95% CI, 0.83-0.95). Among variables (staining location, extent, and intensity), staining of the basal/parabasal layers was a consistent feature in cases with consensus for positive results (20/20). Of the 67 H&E diagnoses with conflicting p16 results, participants modified 32 (48%), downgrading 23 HSILs and upgrading 9 non-HSILs.ConclusionsAlthough p16 increased interobserver agreement, disagreement remained considerable regarding intermediate lesions. p16 expression, particularly if negative, can reduce unwarranted HSIL diagnoses and unnecessary treatment.

Published
2021

11. Refined criteria for p53 expression in ovarian mucinous tumours are highly concordant with TP53 mutation status, but p53 expression/TP53 status lack prognostic significance

Author

Dundr, Pavel, Hájková, Nikola, Kendall Bártů, Michaela, Cibula, David, Drozenová, Jana, Fabian, Pavel, Fadare, Oluwole, Frühauf, Filip, Hausnerová, Jitka, Hojný, Jan, Laco, Jan, Lax, Sigurd F., Matěj, Radoslav, Méhes, Gábor, Michálková, Romana, Němejcová, Kristýna, Singh, Naveena, Stolnicu, Simona, Švajdler, Marián, Zima, Tomáš, McCluggage, W. Glenn, and Stružinská, Ivana

Published
2023
Full Text
View/download PDF

16. The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance

Author

Dundr, Pavel, Bazalová, Barbora, Bártů, Michaela, Bosse, Tjalling, Drozenová, Jana, Fabian, Pavel, Fadare, Oluwole, Hausnerová, Jitka, Jakša, Radek, Laco, Jan, Lax, Sigurd F., Matěj, Radoslav, McCluggage, W. Glenn, Méhes, Gábor, Michálková, Romana, Němejcová, Kristýna, Singh, Naveena, Stolnicu, Simona, Škapa, Petr, Švajdler, Marián, and Stružinská, Ivana

Published
2022
Full Text
View/download PDF

17. Primary Mucinous Tumors of the Ovary: An Interobserver Reproducibility and Detailed Molecular Study Reveals Significant Overlap Between Diagnostic Categories

Author

Dundr, Pavel, Bártů, Michaela, Bosse, Tjalling, Bui, Quang Hiep, Cibula, David, Drozenová, Jana, Fabian, Pavel, Fadare, Oluwole, Hausnerová, Jitka, Hojný, Jan, Hájková, Nikola, Jakša, Radek, Laco, Jan, Lax, Sigurd F., Matěj, Radoslav, Méhes, Gábor, Michálková, Romana, Šafanda, Adam, Němejcová, Kristýna, Singh, Naveena, Stolnicu, Simona, Švajdler, Marián, Zima, Tomáš, Stružinská, Ivana, and McCluggage, W. Glenn

Published
2023
Full Text
View/download PDF

34. SOX17 expression in mesonephric‐like adenocarcinomas and mesonephric remnants/hyperplasia of the female genital tract: Expanding its utility as a Müllerian biomarker.

Author

Zhang, Xiaoming, McCluggage, W. Glenn, Howitt, Brooke E, and Hirsch, Michelle S

Subjects
*GENITALIA, *ENDOMETRIAL cancer, *BIOMARKERS, *ADENOCARCINOMA, *HISTOGENESIS
Abstract

Aims: Recently, SOX17 has emerged as a promising biomarker for non‐mucinous Müllerian (ovarian and endometrial) carcinomas, demonstrating increased specificity in comparison to PAX8 while maintaining similar sensitivity. However, expression of SOX17 in mesonephric‐like adenocarcinoma (MLA), a carcinoma of the female genital tract with uncertain, but probably Müllerian histogenesis, remains unexplored. This study aims to address this gap. Methods and results: SOX17 immunohistochemistry was performed on whole tissue sections from 68 MLAs originating from the endometrium or ovary and seven cervical mesonephric carcinomas, as well as six mesonephric remnants/hyperplasias. Using a four‐tiered scoring system based on distribution and intensity of staining, 68% of MLA displayed a negative/low (< 10%) SOX17 expression pattern, which contrasts with the high expression observed in most Müllerian carcinomas. However, 22% of MLA demonstrated high SOX17 expression, similar to other endometrial and ovarian carcinomas. Similarly, five of seven (72%) mesonephric carcinomas of the cervix were SOX17‐negative, but two cases (28%) were positive. All mesonephric remnants/hyperplasias were SOX17 negative. Conclusions: The majority of MLA are negative or exhibit low SOX17 expression, in contrast to the diffuse and strong expression commonly seen in other types of Müllerian carcinoma. However, a subset of MLAs demonstrate high SOX17 expression. Therefore, absence of SOX17 staining is supportive for MLA when the differential includes another non‐mucinous Müllerian carcinoma. SOX17 may also be useful for differentiating mesonephric remnants/hyperplasias from Müllerian malignancies and benign Müllerian glandular lesions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. STK11 (LKB1) immunohistochemistry is a sensitive and specific marker for STK11 adnexal tumours.

Author

Dehghani, Amir, Sharma, Aarti E, Siegmund, Stephanie E, Carreon, Chrystalle K, Stewart, Colin J R, Medeiros, Fabiola, Mirkovic, Jelena, Nucci, Marisa R, Crum, Christopher P, Hornick, Jason L, Howitt, Brooke E, McCluggage, W Glenn, and Kolin, David L

Subjects
MUCINOUS adenocarcinoma, GRANULOSA cells, SERTOLI cells, LEYDIG cells, ELECTRONIC publications, FALLOPIAN tubes
Abstract

Aims: STK11 adnexal tumour is a rare, recently described malignant neoplasm that is associated with Peutz–Jeghers syndrome. [Correction added on 3 October 2024, after first online publication: 'ST11' in preceding sentence has been corrected to 'STK11' in this version.] It predominantly originates from the para‐adnexal soft tissues and often shows secondary involvement of the fallopian tube and ovary. STK11 adnexal tumours have a broad differential diagnosis due to their variable morphology and non‐specific immunoprofile, and diagnostic confirmation currently requires sequencing to identify an STK11 mutation. We investigate the diagnostic utility of STK11 (LKB1) immunohistochemistry (IHC) in a cohort of STK11 adnexal tumours and morphological mimics. Methods and results: IHC for STK11 was performed on 122 tumours, including 17 STK11 adnexal tumours and 105 morphological mimics (10 female adnexal tumours of Wolffian origin, 22 adult granulosa cell tumours, 10 juvenile granulosa cell tumours, four Sertoli–Leydig cell tumours, two Leydig cell tumours, one Sertoli cell tumour, one steroid cell tumour, four extra‐ovarian sex cord‐stromal tumours, 16 ovarian endometrioid carcinomas, eight tubo‐ovarian high‐grade serous carcinomas, five ovarian mesonephric‐like adenocarcinomas, 14 ovarian carcinosarcomas, five peritoneal malignant mesotheliomas, two pelvic plexiform leiomyomata and one ovarian solid pseudopapillary tumour). All STK11 adnexal tumours showed complete loss of cytoplasmic staining for STK11. All other tumour types showed retained cytoplasmic staining, except for one endometrioid carcinoma with mucinous differentiation which showed complete loss of STK11 expression and a high‐grade serous carcinoma with subclonal loss. Conclusions: STK11 is a highly sensitive and specific immunohistochemical marker for distinguishing STK11 adnexal tumour from its histological mimics, and can obviate the need for confirmatory molecular studies in the appropriate morphological context. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Gastric‐type glandular lesions of the female genital tract excluding the cervix: emerging pathological entities.

Author

Wong, Richard W‐C, Talia, Karen L, and McCluggage, W Glenn

Subjects
GENITALIA, HUMAN papillomavirus, PEUTZ-Jeghers syndrome, FEMALE reproductive organs, PRECANCEROUS conditions, FALLOPIAN tubes
Abstract

In the last two decades or so, a spectrum of benign, premalignant and malignant cervical glandular lesions exhibiting gastric differentiation has been described, with gastric‐type adenocarcinoma representing the most common human papillomavirus (HPV)‐independent cervical adenocarcinoma. More recently, limited literature has reported a variety of gastric‐type glandular lesions at other sites within the female genital tract and, as in the cervix (the most common site for these lesions), a spectrum of benign, premalignant and malignant lesions has been proposed. We provide an update and review of the emerging spectrum of gastric‐type glandular lesions at female genital tract sites other than the cervix. In the endometrium, putative gastric‐type glandular lesions include mucinous metaplasia of gastric‐type, atypical mucinous proliferation of gastric‐type and gastric‐type adenocarcinoma. Similarly in the vagina, gastric‐type adenosis, atypical adenosis and adenocarcinoma have been described. There have also been occasional reports of gastric‐type lesions involving the ovary and fallopian tube. We provide guidance on how to recognise gastric‐type lesions morphologically and immunophenotypically and stress that sometimes these lesions occur at more than one site within the female genital tract (synchronous/multifocal gastric‐type lesions of the female genital tract), sometimes in association with Peutz–Jeghers syndrome. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. High-grade transformation of low-grade endometrial stromal sarcomas lacking YWHAE and BCOR genetic abnormalities

Author

Zou, Youran, Turashvili, Gulisa, Soslow, Robert A., Park, Kay J., Croce, Sabrina, McCluggage, W. Glenn, Stewart, Colin J.R., Oda, Yoshinao, Oliva, Esther, Young, Robert H., Da Cruz Paula, Arnaud, Dessources, Kimberly, Ashley, Charles W., Hensley, Martee L., Yip, Stephen, Weigelt, Britta, Benayed, Ryma, Antonescu, Cristina R., Lee, Cheng-Han, and Chiang, Sarah

Published
2020
Full Text
View/download PDF

46. The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type

Author

Witkowski, Leora, Goudie, Catherine, Ramos, Pilar, Boshari, Talia, Brunet, Jean-Sebastien, Karnezis, Anthony N, Longy, Michel, Knost, James A, Saloustros, Emmanouil, McCluggage, W Glenn, Stewart, Colin JR, Hendricks, William PD, Cunliffe, Heather, Huntsman, David G, Pautier, Patricia, Levine, Douglas A, Trent, Jeffrey M, Berchuck, Andrew, Hasselblatt, Martin, and Foulkes, William D

Subjects
Cancer, Stem Cell Research, Clinical Research, Adolescent, Adult, Age Factors, Carcinoma, Small Cell, Child, Cohort Studies, DNA Helicases, Female, Germ-Line Mutation, Humans, Hypercalcemia, Kaplan-Meier Estimate, Neoplasm Staging, Nuclear Proteins, Ovarian Neoplasms, Prognosis, Transcription Factors, Young Adult, Ovarian cancer, Chemotherapy, Stem cell rescue, SCCOHT, SMARCA4, Mutation, Oncology and Carcinogenesis, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis
Abstract

ObjectiveSmall cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is an aggressive tumor, with long term survival at ~30% in early stage disease. SCCOHT is caused by germline and somatic SMARCA4 mutations, but the effect of the mutation type on patients remains unknown. Furthermore, the rarity of SCCOHT has resulted in varied treatment, with no standardized protocols. We analyzed 293 cases to determine the effect of treatment modalities and SMARCA4 mutations on patient diagnosis and outcome.MethodsIn 293 SCCOHT patients we collected information on age and stage at diagnosis, treatment modality (surgery, chemotherapy, radiotherapy, and/or high-dose chemotherapy with autologous stem cell rescue (HDC-aSCR)), SMARCA4 mutation origin (germline/somatic), and overall survival. Cox analysis and log-rank tests were performed on 257 cases with available survival data.ResultsThe strongest prognostic factors were stage at diagnosis (p=2.72e-15) and treatment modality (p=3.87e-13). For FIGO stages II-IV, 5-year survival was 71% for patients who received HDC-aSCR, compared to 25% in patients who received conventional chemotherapy alone following surgery (p=0.002). Patients aged ≥40 had a worse outcome than younger patients (p=0.04). Twenty-six of 60 tested patients carried a germline SMARCA4 mutation, including all patients diagnosed

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results